NCT05188469 - Study to Assess the Safety, Tolerability and Explore the Immunogenicity of EG-COVID and EG-COVARo in Healthy Adult Volunteers | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

March 22, 2022

Primary Completion Date

May 29, 2024

Study Completion Date

February 28, 2025

Conditions

COVID-19 Vaccine

Interventions

DRUG

EG-COVID-003

"Subjects will receive one, two or three single IM vaccination(s), 3 weeks apart, the subjects will be enrolled to treatment at a ratio of 1:1 (Phase 1: n=10, Phase 2a: 50 per treatment)~EG-COVID-003 0.5mL (mRNA 100μg)~Route of administration: Intramuscular injection"

DRUG

EG-COVID-001

"Subjects will receive one, two or three single IM vaccinations, 3 weeks apart, the subjects will be enrolled to treatment at a ratio of 1:1 (Phase 1: n=10, Phase 2a: 50 per treatment)~EG-COVID-001 0.5mL (mRNA 200μg)~Route of administration: Intramuscular injection"

DRUG

A: EG-COVID

"Subjects will receive two single IM vaccinations, 3 weeks apart, the subjects will be enrolled to treatment~Component Description (per dose):~EG-COVID 0.5mL (mRNA 400μg)~Route of administration: Intramuscular injection"

DRUG

B: EG-COVID

"Subjects will receive two single IM vaccination(s), 3 weeks apart, the subjects will be enrolled to treatment~Component Description (per dose):~EG-COVID 1mL (mRNA 800μg)~Route of administration: Intramuscular injection"

DRUG

C: EG-COVARo

"Subjects will receive two single IM vaccinations, 3 weeks apart, the subjects will be enrolled to treatment~Component Description (per dose):~EG-COVARo 0.5mL (mRNA 800μg)~Route of administration: Intramuscular injection"

Trial Locations (1)

2010

Holdsworth House, Sydney